To the Editor:

Point-of-care ultrasound (POCUS) has been increasingly used for the efficient detection of cardiorespiratory complications of coronavirus disease 2019 (COVID-19).[@bib1] Cardiac POCUS may have similar benefits to transthoracic echocardiography while decreasing staff exposure to patients with COVID-19. Cardiac POCUS has utility,[@bib1] with up to 50% of patients with COVID-19 having cardiac abnormalities on echocardiography, leading to management changes in nearly one third.[@bib2] POCUS of the lung enables diagnosis of pathologies such as alveolar consolidation and alveolar-interstitial syndrome. The relationship between POCUS findings and COVID-19 outcomes is unknown. The aim of this study was to identify how lung and cardiac POCUS findings in patients with COVID-19 relate to clinical outcomes.

We retrospectively reviewed lung and cardiac POCUS studies performed in patients with COVID-19 and suspected cardiorespiratory involvement at the time of presentation to New York hospitals between April 1, 2020, and May 15, 2020. POCUS was performed by certified emergency department physicians. Lung POCUS was used to identify the presence of A- and B-lines ([Table 1](#tbl1){ref-type="table"} ). Cardiac POCUS was performed according to American Society of Echocardiography recommendations.[@bib3] The study cohort was divided into those who did (group 1) and did not (group 2) develop the primary outcome of death or need for mechanical ventilation.Table 1Patient laboratory parameters, POCUS findings, and clinical outcomes in the total cohort and according to the primary study outcomeLaboratory results, POCUS findings, and clinical outcomesOverall (*N* = 80)Group 1: Death or ventilation (*n* = 35)Group 2: No death or ventilation (*n* = 45)*P*Laboratory parameters Cardiac troponin (ng/mL) Baseline0.03 (0.01--0.16)0.05 (0.02--0.18)0.02 (0.01--0.10).048 Peak0.10 (0.02--0.42)0.13 (0.05--0.46)0.05 (0.01--0.33).046 Brain natriuretic peptide (pg/mL) Baseline88 (27.5--334.2)245 (78--504)44 (16--143).002 Peak116 (30--389)337 (107--734)45 (20--146).002 [d]{.smallcaps}-dimer (μg/mL) Baseline2.1 (1.4--3.7)2.3 (1.6--3.9)2.1 (1.1--3.5).30 Peak3.8 (1.8--10.9)6.1 (3.1--16.9)2.9 (1.7--8.2).02POCUS characteristics POCUS: lung53/80 (66.3)23/35 (65.7)30/45 (66.7).90 A lines10/53 (18.9)4/23 (17.4)6/30 (20.0).80 B lines51/53 (96.2)22/23 (95.7)29/30 (96.7).90 POCUS: cardiac67/80 (83.8)29/35 (88.6)37/45 (82.2).30 LV assessment[∗](#tbl1fnlowast){ref-type="table-fn"} Reduced ejection fraction17/66 (22.7)11/29 (37.9)6/37 (16.2).045 RV assessment[†](#tbl1fndagger){ref-type="table-fn"} RV dilation11/59 (18.6)5/23 (21.7)6/36 (16.7).60 RV dilation + dysfunction9/59 (15.3)4/23 (17.3)5/36 (13.9).70 Pericardial effusion4/44 (9.1)1/18 (5.6)3/26 (11.5).50In-hospital outcomes Death31/80 (38.8)31/35 (88.6)0/45 (0.0)\<.001 ICU admission21/79 (26.6)17/34 (50.0)4/45 (8.9)\<.001 Mechanical ventilation22/80 (27.5)22/35 (62.9)0/45 (0.0)\<.001 ARDS22/72 (30.6)20/34 (58.8)2/38 (5.3)\<.001 Acute kidney injury23/68 (33.8)20/29 (69.0)3/39 (7.7)\<.001 Need for renal replacement therapy6/59 (10.2)6/27 (22.2)0/32 (0.0).005 Stroke1/76 (1.3)1/35 (2.9)0/41 (0.0).30 Shock11/68 (16.2)11/29 (37.9)0/39 (0.0).001[^1][^2][^3][^4][^5]

Patients in group 1 were older (median age, 73 years \[interquartile range, 58--59 years\] vs 62 years \[interquartile range, 52--73 years\]; *P* = .004), but cardiovascular disease risk factors were similar between the groups. All lung POCUS examinations were interpretable. Among cardiac POCUS studies, 99% and 88% had suitable imaging for left ventricular (LV) and right ventricular assessment, respectively. Lung POCUS findings in the two patient groups did not differ, with B-lines being prevalent in both groups. Lung POCUS has limitations in COVID-19 and may not detect centrally located consolidation from bacterial superinfection.

With cardiac POCUS, group 1 patients had a higher incidence of reduced LV ejection fraction (37.9% vs 16.2%; *P* = .045). Sud *et al.* [@bib4] showed that acute LV systolic dysfunction was present in approximately 20% of acutely ill patients with COVID-19 and was due to myocarditis, stress-induced cardiomyopathy, or coronary thrombosis. In the present study, it is possible that patients had preexisting LV dysfunction unrelated to COVID-19. Cardiac POCUS has a critical role in the management of patients with COVID-19. Our study showed that cardiac POCUS may risk-stratify acutely ill patients with COVID-19, on the basis of LV function, and identify patients with preexisting or new LV dysfunction who are at higher risk for adverse outcomes. The incidence of abnormal right ventricular findings was lower than in prior studies[@bib4]; this may be explained by POCUS evaluation early in the clinical course, before further development of factors known to precipitate right ventricular pathology, including pulmonary embolism, progressive lung infection, hypoxia, and mechanical ventilation. POCUS may have utility in patients with suspected cardiac complications of COVID-19, by excluding cardiac involvement or triggering transthoracic echocardiography or computed tomography if POCUS imaging is insufficient.[@bib5]

To our knowledge, this is the first study to evaluate cardiac and lung POCUS findings in relation to clinical outcomes in patients with COVID-19. The vast majority of POCUS studies were interpretable. The study was limited by being retrospective in nature with a small study population. Selection bias was relevant, as only the most ill patients with COVID-19 underwent POCUS. Larger POCUS studies of patients with different levels of risk profiles related to COVID-19 are required.

[^1]: *ARDS*, Acute respiratory distress syndrome; *ICU*, intensive care unit; *RV*, right ventricular.

[^2]: Continuous variables are expressed as mean ± SD and categorical variables as number (percentage). Student\'s *t* test was used for continuous variables. For data not normally distributed, the Kruskal-Wallis test was used. Chi-square tests were used for categorical variables. A two-tailed α level of 0.05 was considered the threshold for statistical significance for all tests.

[^3]: A-lines were defined as horizontal refractory lines due to air beneath the pleura and indicated the absence of pulmonary edema. B-lines, seen as vertical refractory lines extending from the pleural line to the bottom of the ultrasound image, with motion due to respiration, indicated fluid within the lung parenchyma, the causes of which are multifactorial and include pulmonary edema due to acute or chronic cardiac disease, pneumonia, lung fibrosis.

[^4]: LV function was not reported in one study, leaving 66 cardiac POCUS studies for analysis of LV findings.

[^5]: RV assessment was indeterminate in eight of 67 patients, leaving 59 for RV analysis.
